MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key prod... MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties. Show more
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR...
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES' PR Newswire MARIETTA, Ga., Sept. 4, 2024 Ex-MiMedx Employee Jake Heikkinen Files Counterclaims...
MARIETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (βMIMEDXβ or the βCompanyβ) today announced that members of its senior management will participate in the...
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT PR Newswire MARIETTA, Ga., Aug. 26, 2024 Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for...
MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (βMIMEDXβ or the βCompanyβ) today announced the commercial launch of HELIOGENβ’ Fibrillar Collagen Matrix, a...
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA...
Study adds to the Companyβs growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDXβs first...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (βMIMEDXβ or the βCompanyβ) today announced that it will report its operating and financial results for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.322061191626 | 6.21 | 6.35 | 6.06 | 492519 | 6.18389242 | CS |
4 | -0.37 | -5.60606060606 | 6.6 | 6.975 | 6.06 | 668505 | 6.47554357 | CS |
12 | -0.5 | -7.4294205052 | 6.73 | 7.92 | 6 | 656641 | 6.70968937 | CS |
26 | -1.63 | -20.737913486 | 7.86 | 8.43 | 5.6501 | 726670 | 6.96289168 | CS |
52 | -1.34 | -17.7014531044 | 7.57 | 9.27 | 5.57 | 707561 | 7.32925768 | CS |
156 | 0.33 | 5.59322033898 | 5.9 | 9.27 | 2.43 | 640581 | 5.88575742 | CS |
260 | 2.57 | 70.218579235 | 3.66 | 15.99 | 2.43 | 682705 | 6.93719383 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.